| |
NewswireToday - /newswire/ -
Basel, Switzerland, 01/17/2008 - Genedata, a leading provider of in silico solutions for the pharmaceutical and life sciences industries, today announced an agreement with the Eisai Research Institute (ERI) for the company’s Genedata Expressionist® biomarker discovery platform.
|
| |
Genedata Expressionist is a modular computational platform for biomarker discovery that integrates transcriptomics, proteomics and metabolomics data within a single enterprise software system. With sophisticated high-throughput data processing and automated workflows for quality assessment, statistical analysis and interpretation functionalities, the platform provides a single-point-of-access for all experimental data, including sample information, raw and pre-processed data, analysis results and documentation with reports.
Jens Hoefkens, Managing Director of Genedata Inc., said, “We are very pleased to be working with the Eisai Research Institute in meeting its bio-IT infrastructure needs for biomarker validation. As the latest of an increasing series of Expressionist installations, we view the institute’s choice as further validation of Expressionist’s appeal to researchers seeking a common platform of tools and applications for biomarker identification with stringent quality control and open data sharing.”
About Genedata
Genedata (genedata.com) specializes in discovery informatics for biotech, pharmaceuticals and the life sciences. The Company offers expertise in research informatics combined with open and scalable computational solutions, including Genedata Phylosopher® for integrating, structuring, and analyzing research data; Genedata Screener® for screening analysis lead identification; and Genedata Expressionist® for omics data integration, processing and analysis. Founded in 1997 as a privately held spin off from Novartis, Genedata is headquartered in Basel, Switzerland and has branches in Tokyo (Japan), Munich (Germany), Konstanz (Germany), Boston (USA) and San Francisco (USA).
|